1
TAO: otamixaban not superior to UFH/eptifibatide in NSTE-ACS 0 0 15 20 25 30 10 8 Propo rtion W ith Event, % D aysSince Random ization Unfractionated heparin + eptifibatide Otam ixaban 6 4 2 5 10 Steg et al., JAMA 2013

TAO: otamixaban not superior to UFH/ eptifibatide in NSTE-ACS

Embed Size (px)

DESCRIPTION

TAO: otamixaban not superior to UFH/ eptifibatide in NSTE-ACS. Steg et al., JAMA 2013. - PowerPoint PPT Presentation

Citation preview

Page 1: TAO:  otamixaban not  superior  to UFH/ eptifibatide  in NSTE-ACS

TAO: otamixaban not superior to UFH/eptifibatide in NSTE-ACS

00 15 20 25 30

10

8

Prop

ort

ion

With

Even

t, %

Days Since Randomization

Unfractionated heparin + eptifibatide

Otamixaban6

4

2

5 10

Steg et al., JAMA 2013